Weight-Loss Pill Hype Lifts LLY but Price Pressure Persists

What happened

Early data from oral weight-loss pills, including Lilly's Foundayo, have boosted shares of Novo Nordisk and Eli Lilly, as investors bet these easier-to-take drugs will expand the obesity market to millions more patients. However, Lilly's Q1'26 results already revealed a 13% consolidated price headwind, partly offset by one-time rebate adjustments, indicating that the market's optimism may overlook persistent gross-to-net erosion. The DeepValue report maintains a WAIT rating with an attractive entry of $850, noting that the stock's current $963 price already prices in sustained GLP-1 growth but leaves little room for further pricing deterioration. Foundayo's launch and the upcoming Medicare GLP-1 Bridge program could drive new-to-class volume, but the key risk remains whether volume growth can outpace accelerating discounts and rebates. The critical test will come in the next 6-12 months as oral competition intensifies and pricing data from Q3 and Q4 2026 reveal whether the 'expand the market' narrative translates into durable net revenue growth.

Implication

Investors should remain patient. The positive sentiment around oral GLP-1s is real but the fundamental pricing headwinds are not yet discounted. Wait for at least two quarters of data post-Foundayo and post-Medicare Bridge to confirm that new-to-class starts are incremental and that consolidated price headwind stabilizes below -7%. Until then, the risk-reward favors waiting for a better entry near $850.

Thesis delta

The market is increasingly pricing in the 'category expansion' thesis from oral GLP-1s, but the DeepValue analysis highlights that pricing pressure is already manifesting. The thesis shift is from 'scaling volumes alone' to 'scaling volumes while defending net price.' If oral pills merely shift patients from injectables or require deeper discounts, the bull case breaks. The next few quarters will determine whether volume growth can offset price compression, altering the investment thesis from 'buy on expansion' to 'wait on price clarity.'